|
GOSR2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66311409088848E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.07700531720911E-11 |
| Normal-vs-Stage2 |
1.772570E-04 |
| Normal-vs-Stage3 |
6.66133814775094E-16 |
| Normal-vs-Stage4 |
1.67155178587564E-12 |
| Stage1-vs-Stage2 |
9.689800E-02 |
| Stage1-vs-Stage3 |
1.406020E-02 |
| Stage1-vs-Stage4 |
8.241100E-03 |
| Stage2-vs-Stage3 |
1.002620E-03 |
| Stage2-vs-Stage4 |
6.822600E-04 |
| Stage3-vs-Stage4 |
4.061200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.44249065417534E-15 |
| Normal-vs-AfricanAmerican |
2.56639999995922E-06 |
| Normal-vs-Asian |
1.23830000031688E-07 |
| Caucasian-vs-AfricanAmerican |
4.892200E-01 |
| Caucasian-vs-Asian |
3.476600E-01 |
| AfricanAmerican-vs-Asian |
9.856400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.92068583260152E-13 |
| Normal-vs-Female |
2.6594282331871E-12 |
| Male-vs-Female |
9.031600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.77610046062193E-10 |
| Normal-vs-Age(41-60Yrs) |
1.53554946535905E-12 |
| Normal-vs-Age(61-80Yrs) |
2.94453350591084E-12 |
| Normal-vs-Age(81-100Yrs) |
8.039200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.306600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.261800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.018200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.991200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.537800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.322600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.7398799999957E-05 |
| Classical-VS-Follicular |
2.780200E-01 |
| Classical-VS-Other |
2.693800E-02 |
| Classical-VS-Normal |
1.72395431263794E-12 |
| Tall-VS-Follicular |
2.43829999999612E-05 |
| Tall-VS-Other |
6.516600E-01 |
| Tall-VS-Normal |
1.11022302462516E-16 |
| Follicular-VS-Other |
4.313600E-02 |
| Follicular-VS-Normal |
3.43810000025258E-07 |
| Other-VS-Normal |
5.88350000052529E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.9066974361931E-11 |
| Normal-vs-N1 |
1.05504494030129E-12 |
| N0-vs-N1 |
2.822300E-03 |
|
|
